#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Antiphospholipid syndrome Familial hypertriglyceridaemia Myasthenia gravis Dementia Alzheimer's type Toxic epidermal necrolysis Neonatal alloimmune thrombocytopenia Thromboangiitis obliterans Rhabdomyosarcoma recurrent Kaposi's sarcoma Ichthyosis Head and neck cancer Polycystic liver disease Cutaneous lupus erythematosus Follicular lymphoma Metachromatic leukodystrophy More trials…

    Learn about Rare Diseases

    Rhabdoid tumour Hairy cell leukaemia – Life with Disease Marginal zone lymphoma refractory – Life with Disease Splenic marginal zone lymphoma – Life with Disease Friedreich’s ataxia – Diagnostics Tuberous sclerosis complex – Trials in Disease Haemophilia B without inhibitors – Treatment Hypereosinophilic syndrome Marfan’s syndrome Urea cycle disorder More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Promazine Hydrochloride Lu Ag09222 Ranibizumab Eribulin Mesylate VG801-2 Capmatinib [99MTC]PSMA I&S Specific Nucleic Acid Sna-Xfsc Egl-001 Neostigmine Methylsulfate Streptococcus Pneumoniae Isoprenaline Hydrochloride Terbinafine Hydrochloride Ecoo75 Rivaroxaban Vorinostat KETOROLAC TROMETAMOL Romidepsin Sulfasalazine Enoxaparin Sodium More therapies…

    Learn about Your Condition

    Astrocytoma malignant Cutibacterium acnes infection Craniopharyngioma Ejection fraction normal Benign renal neoplasm Pleomorphic leiomyosarcoma Post procedural oedema Lysosomal storage disorder Medulloblastoma recurrent Breast cancer recurrent Ear discomfort Supranuclear palsy Thrombosis Inguinal hernia Chronic hepatitis B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinikum Nuernberg

Klinikum Nuernberg

Prof.-Ernst-Nathan-Strasse 1, St. Johannis, Nürnberg, 90419, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Hydrocortisone for Patients Undergoing Pancreatic Surgery

    Recruiting

    4 1 1
    Investigated Drugs:
    • Hydrocortisone
    • Sodium Chloride
    Germany

  • Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Treosulfan
    • Fludarabine
    • Melphalan
    Germany

  • Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Procarbazine
    • Busulfan
    • Carmustine
    Austria Germany

  • Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

    Recruiting

    3 1 1
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Navtemadlin
    • Ondansetron
    Austria Belgium Croatia Czechia France Germany +7

  • Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

    Recruiting

    4 1
    Investigated Drugs:
    • Recombinant Human Surfactant Protein-D
    Belgium Czechia France Germany Italy Poland +2

  • Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Imatinib
    • Ponatinib
    • Blinatumomab
    Germany

  • Study on Midostaurin and Gemtuzumab Ozogamicin for Adults with Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Midostaurin
    • Daunorubicin Hydrochloride
    • Gemtuzumab Ozogamicin
    Germany

  • Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Disodium Folinate
    • Calcium Folinate Pentahydrate
    • Irinotecan Hydrochloride Trihydrate
    Germany

  • Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

    Recruiting

    4 1 1
    Investigated Drugs:
    • Pembrolizumab
    • Resiquimod Sulfate
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Carfilzomib
    Belgium Croatia Czechia Denmark Finland France +10
Previous Page
1 2 3 4 5 … 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!